血栓形成机制与抗血栓药物作用靶点研究进展
Research Progress on Thrombus Formation Mechanisms and Antithrombotic Drug Targets
DOI: 10.12677/PI.2023.125048, PDF,   
作者: 罗晓晓:南京中医药大学,医学院?整合医学学院,江苏 南京;中国药科大学基础医学与临床药学学院,江苏 南京;王玉荣*:中国药科大学基础医学与临床药学学院,江苏 南京;徐 渊*:南京中医药大学,医学院?整合医学学院,江苏 南京
关键词: 血栓形成机制药物作用靶点研究进展Mechanisms of Thrombus Formation Drug Targets Research Progress
摘要: 血栓形成即局部血液凝固,可能发生在动脉或静脉循环中,是人类健康的主要威胁因素之一。了解动脉和静脉血栓形成的机制,并寻找适当的抗血栓治疗靶点对于预防和治疗相关疾病至关重要。本文综述了动脉和静脉血栓形成的机制,并对抗血栓药物的作用靶点研究进展进行了总结。动脉血栓形成主要涉及血小板活化、黏附、聚集、凝血级联反应的激活等因素,而静脉血栓形成则包括血淤、血液本身以及血管内皮细胞变化等过程。目前,针对动脉和静脉血栓形成的抗血栓药物研究主要集中在抑制血小板活化、抗凝以及促进血栓溶解等方面。通过总结动脉和静脉血栓形成机制及抗血栓药物作用靶点的研究进展,本文将为开发更有效的抗血栓治疗策略提供重要参考。
Abstract: Thrombus formation, which refers to local blood coagulation, can occur in both arterial and venous circulation and represents a major health threat to humans. Understanding the mechanisms underlying arterial and venous thrombus formation and identifying appropriate therapeutic targets for antithrombotic treatment are crucial for the prevention and management of related diseases. In this review, we summarize the mechanisms of arterial and venous thrombus formation and provide an overview of the research progress on therapeutic targets for antithrombotic drugs. Arterial thrombus formation primarily involves factors such as platelet activation, adhesion, aggregation, and activation of the coagulation cascade, while venous thrombus formation encompasses processes including stasis of blood, intrinsic properties of blood, and changes in endothelial cells. Currently, research on antithrombotic drugs targeting arterial and venous thrombus formation primarily focuses on inhibiting platelet activation, anticoagulation, and promoting thrombus dissolution. By summarizing the mechanisms of arterial and venous thrombus formation and the research progress on therapeutic targets for antithrombotic drugs, this article provides important insights for the development of more effective antithrombotic treatment strategies.
文章引用:罗晓晓, 王玉荣, 徐渊. 血栓形成机制与抗血栓药物作用靶点研究进展[J]. 药物资讯, 2023, 12(5): 401-408. https://doi.org/10.12677/PI.2023.125048

参考文献

[1] 庞兴学, 王显. 血栓形成的过程与机制研究进展[J]. 医学综述, 2011, 17(11): 1613-1616.
[2] ISTH Steering Committee for World Thrombosis Day (2014) Thrombosis: A Major Contributor to the Global Disease Burden. Journal of Thrombosis and Haemostasis: JTH, 12, 1580-1590. [Google Scholar] [CrossRef] [PubMed]
[3] Wolberg, A.S., Rosendaal, F.R., Weitz, J.I., et al. (2015) Venous Thrombosis. Nature Reviews Disease Primers, 1, Article No. 15006. [Google Scholar] [CrossRef] [PubMed]
[4] Lippi, G., Franchini, M. and Targher, G. (2011) Arterial Thrombus For-mation in Cardiovascular Disease. Nature Reviews Cardiology, 8, 502-512. [Google Scholar] [CrossRef] [PubMed]
[5] Mackman, N. (2012) New Insights into the Mechanisms of Venous Thrombosis. The Journal of Clinical Investigation, 122, 2331-2336. [Google Scholar] [CrossRef
[6] Asada, Y., Yamashita, A., Sato, Y. and Hatakeyama, K. (2020) Pathophysiology of Atherothrombosis: Mechanisms of Throm-bus Formation on Disrupted Atherosclerotic Plaques. Pathology International, 70, 309-322. [Google Scholar] [CrossRef] [PubMed]
[7] Li, X., Guo, T., Feng, Q., et al. (2022) Progress of Thrombus Formation and Research on the Structure-Activity Relationship for Antithrombotic Drugs. European Journal of Medicinal Chemis-try, 228, Article ID: 114035. [Google Scholar] [CrossRef] [PubMed]
[8] Mackman, N. (2008) Triggers, Targets and Treatments for Thrombosis. Nature, 451, 914-918. [Google Scholar] [CrossRef] [PubMed]
[9] Duffett, L. (2022) Deep Venous Thrombosis. Annals of Internal Medicine, 175, ITC129-ITC144. [Google Scholar] [CrossRef
[10] Munnix, I.C.A., Cosemans, J.M.E.M., Auger, J.M. and Heemskerk, J.W.M. (2009) Platelet Response Heterogeneity in Thrombus Formation. Thrombosis and Haemostasis, 102, 1149-1156. [Google Scholar] [CrossRef
[11] 史旭波, 胡大一. 血栓形成与凝血机制及调节[J]. 临床荟萃, 2007, 22(14): 989-991.
[12] Bryckaert, M., Rosa, J.P., Denis, C.V. and Lenting, P.J. (2015) Of von Willebrand Factor and Platelets. Cellular and Molecular Life Sciences: CMLS, 72, 307-326. [Google Scholar] [CrossRef] [PubMed]
[13] Prasannan, N. and Scully, M. (2021) Novel Antiplatelet Strategies Targeting VWF and GPIb. Platelets, 32, 42-46. [Google Scholar] [CrossRef] [PubMed]
[14] Fujimura, Y., Titani, K., Holland, L.Z., et al. (1986) von Willebrand Factor: A Reduced and Alkylated 52/48-kDa Fragment Beginning at Amino Acid Residue 449 Contains the Domain Interacting with Platelet Glycoprotein Ib. The Journal of Biological Chemistry, 261, 381-385. [Google Scholar] [CrossRef
[15] Robert, A., Shen, Y., Elizabeth, G., et al. (1999) The Glyco-protein Ib-IX-V Complex in Platelet Adhesion and Signaling. Thrombosis and Haemostasis, 81, 357-364. [Google Scholar] [CrossRef
[16] Versteeg, H.H., Heemskerk, J.W., Levi, M. and Reitsma, P.H. (2013) New Fundamentals in Hemostasis. Physiological Reviews, 93, 327-358. [Google Scholar] [CrossRef] [PubMed]
[17] Jackson, S.P. (2011) Arterial Thrombosis—Insidious, Unpre-dictable and Deadly. Nature Medicine, 17, 1423-1436. [Google Scholar] [CrossRef] [PubMed]
[18] Zaffran, Y., Meyer, S.C., Negrescu, E., Reddy, K.B. and Fox, J.E.B. (2000) Signaling across the Platelet Adhesion Receptor Glycoprotein Ib-IX Induces αIIbβ3 Activation both in Platelets and a Transfected Chinese Hamster Ovary Cell System. The Journal of Biological Chemistry, 275, 16779-16787. [Google Scholar] [CrossRef] [PubMed]
[19] Jackson, S.P., Nesbitt, W.S. and Westein, E. (2009) Dynamics of Platelet Thrombus Formation. Journal of Thrombosis and Haemostasis: JTH, 7, 17-20. [Google Scholar] [CrossRef] [PubMed]
[20] De Meyer, S.F., De Maeyer, B., Deckmyn, H. and Vanhoorelbeke, K. (2009) Von Willebrand Factor: Drug and Drug Target. Cardiovascular and Hematological Disorders Drug Targets, 9, 9-20. [Google Scholar] [CrossRef] [PubMed]
[21] O’Connor, S.D., Taylor, A.J., Williams, E.C. and Winter, T.C. (2009) Coagulation Concepts Update. AJR American Journal of Roentgenology, 193, 1656-1664. [Google Scholar] [CrossRef
[22] van der Meijden, P.E., Munnix, I.C., Auger, J.M., et al. (2009) Dual Role of Collagen in Factor XII-Dependent Thrombus Formation. Blood, 114, 881-890. [Google Scholar] [CrossRef] [PubMed]
[23] Mackman, N., Tilley, R.E. and Key, N.S. (2007) Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1687-1693. [Google Scholar] [CrossRef
[24] Reininger, A.J., Bernlochner, I., Penz, S.M., et al. (2010) A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atheroscleroticplaques. Journal of the American College of Cardiology, 55, 1147-1158. [Google Scholar] [CrossRef] [PubMed]
[25] Mattheij, N.J., Swieringa, F., Mastenbroek, T.G., et al. (2016) Coated Platelets Function in Platelet-Dependent Fibrin Formation via Integrin αIIbβ3 and Transglutaminase Factor XIII. Haematologica, 101, 427-436. [Google Scholar] [CrossRef] [PubMed]
[26] Brinjikji, W., Madalina Mereuta, O., Dai, D., et al. (2021) Mechanisms of Fibrinolysis Resistance and Potential Targets for Thrombolysis in Acute Ischaemic Stroke: Lessons from Retrieved Stroke Emboli. Stroke and Vascular Neurology, 6, 658-667. [Google Scholar] [CrossRef] [PubMed]
[27] Cushman, M. (2007) Epidemiology and Risk Factors for Venous Thrombosis. Seminars in Hematology, 4, 62-69. [Google Scholar] [CrossRef] [PubMed]
[28] Noble, S. and Pasi, J. (2010) Epidemiology and Patho-physiology of Cancer-Associated Thrombosis. British Journal of Cancer, 102, S2-S9. [Google Scholar] [CrossRef] [PubMed]
[29] Allman-Farinelli, M.A. (2011) Obesity and Venous Thrombosis: A Review. Seminars in Thrombosis and Hemostasis, 37, 903-907. [Google Scholar] [CrossRef] [PubMed]
[30] 孙启铭, 张国忠, 韩业兴, 谷建平, 李瑞利, 冯国伟. 静脉血栓形成及引发肺栓塞的机制探讨[C]//中国法医学会,公安部物证鉴定中心. 中国法医学理论与实践创新成果精选——全国第九次法医学术交流会论文集: 2013年卷. 北京: 中国人民公安大学出版社, 2013: 35-37.
[31] Watson, S.P. (2009) Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis. Current Pharmaceutical Design, 15, 1358-1372. [Google Scholar] [CrossRef] [PubMed]
[32] Di Perri, T., Notari, M. and Assogna, G. (1991) Ridogrel, a New Platelet Antiaggregant Molecule with a Double Mechanism of Action. A Pharmacological and Clinical Profile. Re-centi Progressi in Medicina, 82, 533-540.
[33] Nakamura, K. and Kawahito, K. (2010) Erythrocyte-Protective Effect of Sarpogrelate Hydrochloride (Anplag®), a Selective 5-HT2 Receptor Antagonist: An in Vitro Study. Journal of Artificial Organs, 13, 178-181. [Google Scholar] [CrossRef] [PubMed]
[34] Adams, J.W., Ramirez, J., Shi, Y., et al. (2009) APD791, 3-Methoxy-N-(3-(1-Methyl-1H-Pyrazol-5-yl)-4-(2-Morpholinoethoxy)Phenyl)Benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology. The Journal of Pharmacology and Experimental Therapeutics, 331, 96-103. [Google Scholar] [CrossRef] [PubMed]
[35] Serebruany, V.L., Fortmann, S.D., Rao, S.V., et al. (2016) Vorapaxar and Diplopia: Possible off-Target PAR-Receptor Mismodulation. Thrombosis and Haemostasis, 115, 905-910. [Google Scholar] [CrossRef
[36] Tummala, R. and Rai, M.P. (2022) Glycoprotein IIb/IIIa Inhibitors. In: StatPearls, StatPearls Publishing, Treasure Island.
[37] 季顺东. 血栓形成机制及抗凝药物的药理特点[J]. 中国计划生育和妇产科, 2021, 13(3): 25-28.
[38] Warkentin, T.E., Greinacher, A. and Koster, A. (2008) Bivalirudin. Throm-bosis and Haemostasis, 99, 830-839. [Google Scholar] [CrossRef
[39] McKeage, K. and Plosker, G.L. (2001) Argatroban. Drugs, 61, 515-522. [Google Scholar] [CrossRef] [PubMed]
[40] Lin, S., Wang, Y., Zhang, L. and Guan, W. (2019) Dabigatran Must Be Used Carefully: Literature Review and Recommendations for Management of Adverse Events. Drug Design, Development and Therapy, 13, 1527-1533. [Google Scholar] [CrossRef
[41] Büller, H.R., Prins, M.H., Lensin, A.W., et al. (2012) Oral Rivarox-aban for the Treatment of Symptomatic Pulmonary Embolism. The New England Journal of Medicine, 366, 1287-1297. [Google Scholar] [CrossRef
[42] Agnelli, G., Buller, H.R., Cohen, A., et al. (2013) Apixaban for Ex-tended Treatment of Venous Thromboembolism. The New England Journal of Medicine, 368, 699-708. [Google Scholar] [CrossRef
[43] (2011) Edoxaban Tosylate. American Journal of Cardiovascular Drugs, 11, 129-135. [Google Scholar] [CrossRef] [PubMed]
[44] Zhang, Y., Zhang, M., Tan, L., Pan, N. and Zhang, L. (2019) The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharide. In: Zhang, L., Ed., Glycans and Gly-cosaminoglycans as Clinical Biomarkers and Therapeutics—Part B. Progress in Molecular Biology and Translational Science, Vol. 163, Elsevier, Amsterdam, 41-53. [Google Scholar] [CrossRef] [PubMed]
[45] Onishi, A., St Ange, K., Dordick, J.S. and Linhardt, R.J. (2016) Heparin and Anticoagulation. Frontiers in Bioscience, 21, 1372-1392. [Google Scholar] [CrossRef] [PubMed]
[46] Kunamneni, A. and Durvasula, R. (2014) Streptokinase—A Drug for Thrombo-lytic Therapy: A Patent Review. Recent Advances in Cardiovascular Drug Discovery, 9, 106-121. [Google Scholar] [CrossRef] [PubMed]
[47] Kadir, R.R.A. and Bayraktutan, U. (2020) Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke. Cellular and Molecular Neurobiology, 40, 347-355. [Google Scholar] [CrossRef] [PubMed]
[48] Warach, S.J., Dula, A.N. and Milling Jr., T.J. (2020) Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke, 51, 3440-3451. [Google Scholar] [CrossRef